BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 10403307)

  • 1. Reversible monoclonal lymphadenopathy in autoimmune lymphoproliferative syndrome with functional FAS (CD95/APO-1) deficiency.
    Ströbel P; Nanan R; Gattenlöhner S; Müller-Deubert S; Müller-Hermelink HK; Kreth HW; Marx A
    Am J Surg Pathol; 1999 Jul; 23(7):829-37. PubMed ID: 10403307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia.
    Aspinall AI; Pinto A; Auer IA; Bridges P; Luider J; Dimnik L; Patel KD; Jorgenson K; Woodman RC
    Blood Cells Mol Dis; 1999; 25(3-4):227-38. PubMed ID: 10575548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histologic features of sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome.
    Maric I; Pittaluga S; Dale JK; Niemela JE; Delsol G; Diment J; Rosai J; Raffeld M; Puck JM; Straus SE; Jaffe ES
    Am J Surg Pathol; 2005 Jul; 29(7):903-11. PubMed ID: 15958855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
    Sneller MC; Wang J; Dale JK; Strober W; Middelton LA; Choi Y; Fleisher TA; Lim MS; Jaffe ES; Puck JM; Lenardo MJ; Straus SE
    Blood; 1997 Feb; 89(4):1341-8. PubMed ID: 9028957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression in transgenic mice of dominant interfering Fas mutations: a model for human autoimmune lymphoproliferative syndrome.
    Choi Y; Ramnath VR; Eaton AS; Chen A; Simon-Stoos KL; Kleiner DE; Erikson J; Puck JM
    Clin Immunol; 1999 Oct; 93(1):34-45. PubMed ID: 10497009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined deficiency in CD44 and Fas leads to exacerbation of lymphoproliferative and autoimmune disease.
    Do Y; Rafi-Janajreh AQ; McKallip RJ; Nagarkatti PS; Nagarkatti M
    Int Immunol; 2003 Nov; 15(11):1327-40. PubMed ID: 14565931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation.
    Dianzani U; Bragardo M; DiFranco D; Alliaudi C; Scagni P; Buonfiglio D; Redoglia V; Bonissoni S; Correra A; Dianzani I; Ramenghi U
    Blood; 1997 Apr; 89(8):2871-9. PubMed ID: 9108407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome.
    Rao VK; Dowdell KC; Dale JK; Dugan F; Pesnicak L; Bi LL; Hoffmann V; Penzak S; Avila NA; Fleisher TA; Puck JM; Straus SE
    Am J Hematol; 2007 Dec; 82(12):1049-55. PubMed ID: 17674358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome.
    Janić MD; Brasanac CD; Janković JS; Dokmanović BL; Krstovski RN; Kraguljac Kurtović JN
    Pediatr Blood Cancer; 2009 Dec; 53(6):1117-9. PubMed ID: 19588524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS).
    Dowdell KC; Pesnicak L; Hoffmann V; Steadman K; Remaley AT; Cohen JI; Straus SE; Rao VK
    Exp Hematol; 2009 Apr; 37(4):487-94. PubMed ID: 19217201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological findings in human autoimmune lymphoproliferative syndrome.
    Lim MS; Straus SE; Dale JK; Fleisher TA; Stetler-Stevenson M; Strober W; Sneller MC; Puck JM; Lenardo MJ; Elenitoba-Johnson KS; Lin AY; Raffeld M; Jaffe ES
    Am J Pathol; 1998 Nov; 153(5):1541-50. PubMed ID: 9811346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease.
    Peters AM; Kohfink B; Martin H; Griesinger F; Wörmann B; Gahr M; Roesler J
    Exp Hematol; 1999 May; 27(5):868-74. PubMed ID: 10340403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis.
    Bettinardi A; Brugnoni D; Quiròs-Roldan E; Malagoli A; La Grutta S; Correra A; Notarangelo LD
    Blood; 1997 Feb; 89(3):902-9. PubMed ID: 9028321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new disorder of lymphocyte apoptosis: combination of autoimmunity, infectious lymphadenopathy, double negative T cells, and impaired activation-induced cell death.
    Hundt M; Posovszky C; Schmidt RE
    Immunobiology; 2002 Dec; 206(5):514-8. PubMed ID: 12607726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmune lymphoproliferative syndrome, a disorder of apoptosis.
    Jackson CE; Puck JM
    Curr Opin Pediatr; 1999 Dec; 11(6):521-7. PubMed ID: 10590910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmune lymphoproliferative syndrome in a patient with common variable immunodeficiency: dichotomy of apoptosis.
    Narra MB; Abdou NI
    Ann Allergy Asthma Immunol; 2007 Jun; 98(6):585-8. PubMed ID: 17601274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.
    Fisher GH; Rosenberg FJ; Straus SE; Dale JK; Middleton LA; Lin AY; Strober W; Lenardo MJ; Puck JM
    Cell; 1995 Jun; 81(6):935-46. PubMed ID: 7540117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A genetic disorder of lymphocyte apoptosis involving the fas pathway: the autoimmune lymphoproliferative syndrome.
    Fleisher TA; Straus SE; Bleesing JJ
    Curr Allergy Asthma Rep; 2001 Nov; 1(6):534-40. PubMed ID: 11895618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance.
    Jackson CE; Fischer RE; Hsu AP; Anderson SM; Choi Y; Wang J; Dale JK; Fleisher TA; Middelton LA; Sneller MC; Lenardo MJ; Straus SE; Puck JM
    Am J Hum Genet; 1999 Apr; 64(4):1002-14. PubMed ID: 10090885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer.
    Ramenghi U; Bonissoni S; Migliaretti G; DeFranco S; Bottarel F; Gambaruto C; DiFranco D; Priori R; Conti F; Dianzani I; Valesini G; Merletti F; Dianzani U
    Blood; 2000 May; 95(10):3176-82. PubMed ID: 10807785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.